Modulation of the apelin/APJ system in heart failure and atherosclerosis in man

British Journal of Pharmacology

Volumn 160, Issue 7, 2010, Pages 1785-1795

  Pitkin, Sarah L ^a   Maguire, Janet J ^a   Kuc, Rhoda E ^a   Davenport, Anthony P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

apelin; APJ; atherosclerosis; coronary artery; dilated cardiomyopathy; G protein coupled receptor; human; ischaemic heart disease

Indexed keywords

APELIN; APELIN RECEPTOR; RADIOLIGAND;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIAC PATIENT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CONSTRICTION; DOWN REGULATION; FEMALE; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INOTROPISM; ISCHEMIC HEART DISEASE; LIGAND BINDING; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; RECEPTOR DENSITY; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR TISSUE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, DILATED; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RADIOIMMUNOASSAY; RECEPTORS, G-PROTEIN-COUPLED; YOUNG ADULT;

EID: 77954336925     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00821.x     Document Type: Article

References (44)

1. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A et al. (2005). The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 65:73 82.
2. Atluri P, Morine KJ, Liao GP, Panlilio CM, Berry MF, Hsu VM et al. (2007). Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett 12:127 138.
3. Carpéné C, Dray C, Attane C, Valet P, Portillo MP, Churruca I et al. (2007). Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem 63:359 373.
4. Chen MM, Ashley EA, Deng DXF, Tsalenko A, Deng A, Tabibiazar R et al. (2003). Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108:1432 1439.
5. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA (2006). Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eu J Heart Fail 8:355 360.
6. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R et al. (2008). Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 118:3343 3354.
7. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA (2006). Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 296:177 189.
8. Dec GW, Fuster V (1994). Idiopathic dilated cardiomyopathy. N Engl J Med 331:1564 1575.
9. Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt A et al. (2003). Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Bioch Biophys Res Commun 308:480 485.
10. Hashimoto T, Kihara M, Imai N, Yoshida S, Shimoyamada H, Yasuzaki H et al. (2007). Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 171:1705 1712.
11. Iwanaga Y, Kihara Y, Takenaka H, Kita T (2006). Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 41:798 806.
12. Japp AG, Newby DE (2008). The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 75:1882 1892.
13. Japp AG, Cruden NL, Amer DAB, Li VKY, Goudie EB, Johnston NR et al. (2008). Vascular effects of apelin in vivo in man. J Am Coll Cardiol 52:908 913.
14. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J et al. (2010). Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 121:1818 1827.
15. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T et al. (2004). Apelin is a novel angiogenic factor in retinal endothelial cells. Bioch Biophys Res Commun 325:395 400.
16. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP (2001). I-125 -(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 132:1255 1260.
17. Katugampola SD, Maguire JJ, Kuc RE, Wiley KE, Davenport AP (2002). Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol 80:369 374.
18. Kleinz MJ, Davenport AP (2004). Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Reg Pept 118:119 125.
19. Kleinz MJ, Davenport AP (2005). Emerging roles of apelin in biology and medicine. Pharmacol Ther 107:198 211.
20. Kleinz MJ, Skepper JN, Davenport AP (2005). Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Reg Pept 126:233 240.
21. Kojima Y, Kundu R, Cox CM, Leeper NJ, Anderson JA, Chun HJ et al. (2010). Upregulation of the apelin-APJ pathway promotes neointima formation in the carotid ligation model in mouse. Cardiovasc Res, DOI: 10.1093/cvr/cvq052 Epub ahead of print.
22. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y et al. (2007). Impaired heart contractility in apelin gene deficient mice associated with aging and pressure overload. Circ Res 101:e32 e42.
23. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF (2008). The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol 90:343 349.
24. Lee DK, George SR, O'Dowd BF (2006). Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 27:190 194.
25. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA et al. (2009). Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 296:H1329 H1335.
26. Li F, Li L, Qin X, Pan W, Feng F, Chen F et al. (2008). Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. Front Biosci 13:3786 3792.
27. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP (2009). Pyr1Apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54:598 604.
28. Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y (2004). Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. Faseb J 18:1909 1911.
29. Masri B, Knibiehler B, Audigier Y (2005). Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal 17:415 426.
30. Miettinen KH, Magga J, Vuolteenaho O, Vanninen EJ, Punnonen KR, Ylitalo K et al. (2007). Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Reg Pept 140:178 184.
31. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL et al. (1993). A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136:355 360.
32. Pitkin SL, Maguire JJ, Ashby MJ, Kuc RE, Davenport AP (2007). Identification and measurement of endogenous apelin peptides in the human cardiovascular system. From the Brighton Winter 2007 Meeting: Proceedings of the British Pharmacological Society. WWW document. URL http://www.pa2online.org/ abstract/abstract.jsp?abid=28999&author=pitkin&cat=-1&period=-1
33. Pitkin SL, Ashby MJ, Kuc RE, Maguire JJ, Davenport AP (2008a). Apelin peptides are upregulated in human atherosclerosis. Fundam Clin Pharmacol 22:74 P081.
34. Pitkin SL, Kuc RE, Maguire JJ, Davenport AP (2008b). Upregulation and localisation of apelin in human atherosclerosis. From the Brighton Winter 2008 Meeting: Proceedings of the British Pharmacological Society. WWW document. URL http://www.pa2online.org/abstract/abstract.jsp?abid=29087&author= pitkin&cat=-1&period=-1
35. Pitkin SL, Macaluso NJM, Maguire JJ, Glen RC, Davenport AP (2009). Role for apelin in human atherosclerosis and discovery of novel agonists for its receptor APJ. From the London Winter 2009 Meeting: Proceedings of the British Pharmacological Society. WWW document. URL http://www.pa2online.org/abstract/ abstract.jsp?abid=29431&author=pitkin&cat=-1&period=-1
36. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP (2010). International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology and Function. Pharmacol Rev 62:in press.
37. Puffer BA, Sharron M, Coughlan CM, Baribaud F, McManus CM, Lee B et al. (2000). Expression and coreceptor function of APJ for primate immunodeficiency viruses. Virology 276:435 444.
38. Ronkainen VP, Ronkainen JJ, Hannninen SL, Leskinen H, Ruas JL, Pereira T et al. (2007). Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. Faseb J 21:1821 1830.
39. Salcedo A, Garijo J, Monge L, Fernandez N, Luis Garcia-Villalon A, Sanchez Turrion V et al. (2007). Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. Reg Pept 144:50 55.
40. Sarzani R, Forleo C, Pietrucci F, Capestro A, Soura E, Guida P et al. (2007). The 212A variant of the apj receptor gene for the endogenous inotrope apelin is associated with slower heart failure progression in idiopathic dilated cardiomyopathy. J Card Fail 13:521 529.
41. Sheikh AY, Chun HJ, Glassford AJ, Kundu RK, Kutschka I, Ardigo D et al. (2008). In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol 294:H88 H98.
42. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC (2007). Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 102:518 528.
43. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX et al. (1998). Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Bioch Biophys Res Commun 251:471 476.
44. Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ, Tang CS (2009). Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 30:1144 1152.